Make sure that your vaccines are adjuvant and mercury free. Virus adjuvant MF59 is 5% squalene, 0.5% polysorbate 80 and 0.5% sorbitan trioleate. All have been associated with both long and short term health problems when injected.
http://www.scharp.org/public/redbook/protocol/apxa2.htmThe adjuvant emulsion, MTP-PE/MF59, contains a muramyl tripeptide (MTP) linked covalently with dipalmitoyl phosphatidylethanolamine (PE) and MF59, a microfluidized oil-in-water emulsion. This emulsion, the adjuvant for the HIV-1 SF-2 rgp120, consists of 0.5% polysorbate 80 (Tween 80, polyoxyethylene sorbitan mono-oleate) and 0.5% sorbitan trioleate (Span 85, Arlacel 85) in a citrate buffer. Squalene (5%), a metabolizable lipid, constitutes the oil phase. For most studies, the preparation contains MF59 without MTP-PE.
http://www.who.int/vaccine_safety/topics/adjuvants/squalene/Jun_2006/en/index.htmlSqualene alone is not an adjuvant, but emulsions of squalene with surfactants enhance the immune response when added to antigens. MF59, a proprietary adjuvant containing squalene, is included in a seasonal subunit influenza vaccine licensed by the Italian regulatory authority in 1997 and subsequently by several other countries. The vaccine contains about 10 mg of squalene per dose. Over 22 million doses have been distributed since that time. Reported rates of adverse events and local reactogenicity are not in excess of those that would be expected with other inactivated seasonal flu vaccines, suggesting that squalene in this vaccine poses no significant risk. This vaccine has been administered primarily to individuals aged 65 years and older, for whom the vaccine was licensed.
http://www.gulfwarvets.com/additive.htmTrace amounts of the additive squalene have been found in the anthrax vaccine used to protect U.S. service members from the biological warfare agent, federal health officials have found. The finding contradicts repeated assertions by the Pentagon that squalene is not present in the vaccine.
The federal Food and Drug Administration said its results were based on tests of five lots of the vaccine. The agency did not make clear whether those lots containing squalene were used to inoculate troops during the Persian Gulf War, those receiving the vaccine since a mandatory inoculation program began in 1998, or both. The FDA also did not address potential health problems with the vaccine; agency spokeswoman Lenore Gelb declined to comment.
Squalene's safety was called into question when a 1999 Tulane University study of blood samples taken from sick gulf war veterans detected the presence of antibodies linked to the additive. Some of the samples were taken from soldiers who did not take part in the war; but all presumably received the vaccine. Previously, Congress' watchdog agency, the General Accounting Office, had reported that gulf war veterans were complaining of mysterious, undiagnosed illnesses similar to patients with auto-immune disorders. A Tennessee immunologist, Dr. Pamela B. Asa, concluded those illnesses were caused by exposure to additives in vaccines, the GAO said.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12042063&dopt=AbstractSorbitan Laurate and Sorbitan Trioleate were cocarcinogens in one mouse study ...
http://www.chiroweb.com/archives/18/24/06.htmlIn a follow-up study published earlier this year, a Tennessee immunologist confirmed the findings of the Tulane study and concluded that the mysterious illnesses suffered by Gulf War veterans could have been caused by exposure to additives in vaccines.2 This conclusion was vehemently contested by Pentagon officials, who maintained that squalene was never used in the making of the anthrax vaccine, and that even it were present, it would not cause soldiers to become sick.
As early as this March, the FDA began releasing preliminary information stating that low levels of squalene had indeed been detected in some anthrax vaccines. In a written statement delivered during congressional hearings into the safety of the anthrax vaccine on March 20, the FDA said that test results showed "squalene content was determined to be in a level of low parts-per-billion and was comparable to levels determined in three other lots of the anthrax vaccine."3
On September 28, the FDA released another report showing that trace amounts of squalene were found in five lots of the anthrax vaccine. The FDA did not make clear whether the lots that contained squalene were the same lots used to inoculate troops during the Gulf War, or whether they are being used in the current anthrax vaccination program. A spokesperson for the FDA also declined to comment on any potential health problems associated with the vaccine.
As late as this October, however, the DoD was still insisting that squalene "is not in the anthrax vaccine" and that the substance "has not been used in vaccines ... for a considerable period of time."3
http://darwin.nap.edu/books/030907178X/html/309.htmlSqualene has attracted the interest of arthritis researchers because of its ability to activate the immune system nonspecifically. It was one of the constituents used in the 1970s to create the first animal models of multiple sclerosis, known as experimental allergic encephalomyelitis (EAE) (Beck et al., 1976). Squalene is one of several adjuvants (such as incomplete Freund’s adjuvant) found to induce arthritis in susceptible rat strains and has been used in the generation of animal models of arthritis (Whitehouse et al., 1974; Lorentzen, 1999). The effect is so pronounced that researchers have coined the term “squalene-induced arthritis.” After a single intraarticular injection of 50 μL squalene into Lewis (Yoshino, 1996) and Dark Agouti rats (Yoshino and Yoshino, 1994), animals experienced moderate joint inflammation by day 6, followed by more severe chronic arthritis by day 21. The inflammation was marked by joint swelling and infiltration of CD5+ and αβ+ T cells. Similarly, intradermal injection of 200 μL squalene into Dark Agouti rats produced arthritis (Lorentzen, 1999). Although the mechanisms are not fully understood, the inflammation is blocked by agents that suppress T cells (Yoshino, 1996; Sverdrup et al., 1998) . Animal studies do not report whether injection of squalene produces antisqualene antibodies.
In summary, there is limited published information about squalene toxicity. The human relevance of what has been published is unclear because of species differences in absorption. Squalene has been found to produce arthritis and neuropathology under select conditions in animals; the relevance to humans of these toxicity findings is uncertain.
Printer-friendly format
Email this thread to a friend
Bookmark this thread
(1000+ posts)
Send PM |
Profile |
Ignore
